The inaugural meeting of the International Angelman Syndrome Research Council, known as INSYNC-AS, focused on the translational research landscape in Angelman syndrome (AS), and on prospects for new treatments. The recent assembly of Angelman scientists and experts from around the world was pulled together by the Foundation…
News
Nominations are now open for the worldwide 2022 Black Pearl Awards from Eurordis-Rare Diseases Europe. The 12 award categories recognize individual advocates, policy makers, researchers, organizations, and companies who work to make a difference for the global rare disease community. The deadline for nominations is Sept. 10…
The Foundation for Angelman Syndrome Therapeutics (FAST) has opened a program supporting new research into treating Angelman syndrome by using microRNA (miRNA) to boost UBE3A protein levels. FAST will collaborate with the Gene Therapy Program at the University of Pennsylvania (UPenn) to design this potential therapy, the organization…
At its first virtual investor event, biotech company Centogene set a bold mission: to cure 100 rare diseases within the next decade. A leader in the field of genetic diagnostics, Centogene used the June 22 event to present its strategic priorities, outlining its plans to speed the discovery…
The United Kingdom’s Medicines Healthcare Products Regulatory Agency (MHRA) has authorized a Phase 1/2 clinical trial to test the investigational therapy GTX-102 in children and adolescents with Angelman syndrome. The open-label KIK-AS trial (NCT04259281), which also has been given a green light in Canada, is expected to open enrollment in the…
To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…
Neuren Pharmaceuticals is a step closer to Phase 2 clinical testing of NNZ-2591, its investigational therapy for Angelman syndrome, Phelan–McDermid syndrome, and Pitt Hopkins syndrome, after the company received clear and constructive guidance from the U.S. Food and Drug Administration. All three syndromes are early…
Those who wish to gain practical tools for living optimally with rare diseases are encouraged to attend the annual Living Rare Living Stronger Patient and Family Forum, hosted by the National Organization for Rare Disorders (NORD) and set this year for June 26-27. The conference brings together patients,…
Philanthropists Ryan and Annie Jacob have pledged up to $250,000 to the Foundation for Angelman Syndrome Therapeutics, known as FAST, through a new donation matching program. The Austin, Texas-based couple, who have a son with Angelman syndrome, will match donations up to that amount through FAST’s fundraising initiative,…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…
Recent Posts
- Our nonverbal son’s hospitalization taught us some important lessons
- Angelman clinical trial enrolls children to test new treatment
- Angelman syndrome seizures are unpredictable, but we carry on
- $32.5M to advance rugonersen into late-stage testing for Angelman
- GTX-102 data show continued developmental gains in Angelman
- What standardized assessments miss about my son with Angelman
- Surgery usually corrects misaligned eyes in kids with Angelman, study finds
- The joys and challenges of disability equipment for children with Angelman
- Goals that matter most for our child living with Angelman syndrome
- Home videos may help doctors evaluate Angelman patient skills